Harry Li

Bio:

Harry received a B.S. in chemistry from Nanjing University of Science and Technology, a M.S. in natural product chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and a Ph.D. in organic chemistry from Tokyo Institute of Technology. From 1990 to 1991, Harry was a post-doctoral fellow at Medical Products Department of DuPont Company. After working as a medicinal chemist with DuPont Merck Pharmaceuticals from 1991 to 1995, Harry worked as process chemist at Process R&D department of DuPont Pharmaceuticals Company (1995-2001) and Bristol-Myers Squibb company (2001-2002). He is also an adjunct professor at the University of Delaware and Shanghai Institute of Materia Medica, Chinese Academy of science in China. Harry has over 30 years of combined experiences in all aspects of new drug research and development, including API cGMP manufacturing, solid state chemistry and project managements. Harry is the author of numerous patents and publications including key process and polymorph patents related to several important pharmaceutical compounds. In 2003, he founded Wilmington PharmaTech with three cGMP production facilities and R&D center in Newark, Delaware and one research center in Suzhou, China and serves as President and CEO since.